These data defined a mechanism of DCA in promoting intestinal tumour development through ADAM‐17‐mediated AREG release, leading to activation of EGFR, and represented a potential target for the bile acid–related intestinal cancer prevention and therapy. Here, ADAM17 is linked to intestinal neoplasm.